Hodgkin Lymphoma Outcomes Worse In Medicaid, Uninsured Patients

Share this content:
Patients with Hodgkin lymphoma who have Medicaid or are uninsured have outcomes inferior to those of patients with more favorable insurance.
Patients with Hodgkin lymphoma who have Medicaid or are uninsured have outcomes inferior to those of patients with more favorable insurance.

Patients with Hodgkin lymphoma who have Medicaid or are uninsured have outcomes inferior to those of patients with more favorable insurance, a recent study published online ahead of print in the journal Cancer has shown.

For the study, researchers sought to investigate disparities in overall survival by insurance status in a large population of patients with Hodgkin lymphoma.

Researchers analyzed the data from 45,777 patients with stage I to IV Hodgkin lymphoma from the National Cancer Data Base. Of those, 7.1% were uninsured, 17% had Medicaid, 66.3% had private insurance, 8.2% had managed care, and 1.1% had Medicare.

Results showed that patients with Medicaid or who were uninsured were at a more advanced stage, had higher comorbidity scores, had B symptoms, and were in a lower education/income quartile (all P<0.01).

Researchers found that these patients with unfavorable insurance status were less likely to receive radiotherapy and start chemotherapy quickly. They were also less often treated at an academic/research institution (all P<0.01).

RELATED: Complete Response Rate at 30 Months Correlates with Progression-Free Survival in Follicular Lymphoma

Five-year overall survival rates were 54% for patients with unfavorable insurance status compared with 87% for those with favorable insurance (P<0.01). Unfavorable insurance status was significantly associated with substantially reduced overall survival (HR = 1.60; 95% CI: 1.34, 1.91; P<0.01).

The findings suggest that targeting those patients with unfavorable insurance status and limited access to care may improve clinical outcomes.

Reference

  1. Parikh RR, Grossbard ML, Green BL, et al. Disparities in survival by insurance status in patients with Hodgkin lymphoma. Cancer. 2015. [Epub ahead of print]. doi: 10.1002/cncr.29518.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters